Skip to main content
. 2020 Mar 10;10:4429. doi: 10.1038/s41598-020-61370-y

Figure 5.

Figure 5

PNGase F-treated Gpr176 retains its cAMP-repressive activity. (A) Schematic experimental design for the glycosidase-treated cell suspension GloSensor assay. Dox-treated (+) and untreated (−) cells were resuspended in HBSS with or without PNGase F for 1 h before the GloSensor cAMP assay. (B) Fsk-induced GloSensor activity traces in PNGase F-treated and untreated Flp-In TREx293-Gpr176 (tet-on)/GloSensor (constitutive) cell suspensions. The arrow indicates the start of Fsk treatment. RLU, relative light units. Values (means ± s.d., n = 9 for each data point) are plotted relative to the average peak value obtained in Dox-untreated cells. Insets indicate relative AUC values (means ± s.d., n = 9; ***P < 0.0005, two-tailed unpaired t-test). (C) Immunoblots of representative PNGase F-treated and untreated Flp-In TREx293-Gpr176 (tet-on)/GloSensor (constitutive) cells. The cell suspension samples were immunoblotted for Gpr176 (upper) and Hsp70 (lower). Hsp70 served as a loading control.